Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences has demonstrated expanding operating margins, increasing by 100 basis points, in conjunction with a long-term sales growth target of approximately 10% annually, excluding foreign exchange effects. The company's robust positioning in structural heart therapies, particularly with a revitalized focus on TAVR procedures and the introduction of the Cordella heart failure monitoring device, suggests significant potential for revenue growth and market share expansion. Supporting this positive outlook, physician feedback indicates a forthcoming rise in procedure volumes, further bolstering projections for increased sales and earnings per share in the near term.

The outlook for Edwards Lifesciences's stock is negatively impacted by potential underperformance in the transcatheter aortic valve replacement (TAVR) business, where growth may not meet investor expectations and the total addressable market could be smaller than projected. Additionally, delays in the innovation pipeline for minimally invasive tricuspid and mitral valve products, compounded by a challenging regulatory and reimbursement environment, could hinder sales growth. Finally, macroeconomic factors, increased competition, and issues with market penetration pose further headwinds, contributing to a cautious revenue growth forecast for the company.